隶属于 government of south korea
相关临床试验
14
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
已完成
7
50.0%
尚未招募
2
14.3%
终止
2
14.3%
Unknown
3
21.4%
暂无批准数据
- South Korea's Ministry of Food and Drug Safety approved the Phase 2 IND for GC4006A, GC Biopharma's COVID-19 mRNA vaccine candidate, on September 11. - The Phase 2 trial will compare GC4006A against an active control to determine optimal dose and immunogenicity in healthy adults and elderly people aged 19 to 85. - First patient dosing is planned within the year, with a Phase 3 IND submission targeted for 2027 under a government-funded program aiming for domestic mRNA vaccine self-sufficiency by 2028. - GC Biopharma intends to leverage its validated mRNA-LNP platform to expand beyond COVID-19 into next-generation immuno-oncology therapies and rare genetic disease treatments.
• South Korea's government has unveiled an ambitious five-point strategy to revolutionize its bio-health industry, focusing on innovation in medical services, export growth, and AI-driven R&D advancement. • The country's life sciences sector is experiencing rapid growth through substantial public-private investments, supported by advanced infrastructure and a highly skilled STEM workforce. • Major players like Samsung Biologics, LG Chem, and Celltrion are driving industry growth, while government initiatives provide robust support for biotech startups and research development.
